Celularity Secures $35 Million Strategic License Deal, Strengthens Capital Position to Advance Longevity-Focused Strategy

Core Insights - Celularity Inc. has entered into definitive agreements for a strategic commercialization partnership focused on its placental-derived biomaterials portfolio, expected to close by April 15, 2026 [1][2][3] Financial Aspects - The transaction aims to monetize Celularity's commercial biomaterials portfolio, with the company expecting upfront consideration at closing and potential milestone payments totaling up to $35 million, representing non-dilutive capital [3][9] - Celularity will also receive royalties on future net sales of certain development-stage products upon commercialization [3] Manufacturing and Operations - Celularity will act as the exclusive manufacturer of the licensed products at its FDA-compliant facility in Florham Park, New Jersey, creating an ongoing manufacturing revenue stream [4][9] - The company’s vertically integrated manufacturing infrastructure supports scalable, quality-driven production for both commercial-stage products and next-generation placental-derived cellular therapeutics [4] Strategic Focus - Following the transaction, Celularity will sharpen its focus on longevity medicine, concentrating resources on high-value cellular therapeutics targeting the fundamental mechanisms of aging [5][7] - The company plans to expand its commercial and clinical opportunities in jurisdictions that allow investigational use of cellular and biologic technologies, including Florida, Texas, and Arizona [7] Organizational Changes - Personnel associated with the commercial and product development biomaterials activities are expected to transition to the commercial partner, and Celularity will reduce its workforce to lower operating expenses [6] - This organizational realignment is designed to enhance capital efficiency by concentrating investment on high-value clinical and manufacturing initiatives [6]